Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension

Tamila Martynyuk, Kirill Zykov, Olga Antonova, Olga Arkhipova, Ekaterina Kobal, Valery Masenko, Sergey Nakonechnikov, Irina Chazova
European Respiratory Journal 2012 40: P407; DOI:
Tamila Martynyuk
1Department of Systemic Hypertension, Russian Cardiology Research-and-Production Complex, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirill Zykov
1Department of Systemic Hypertension, Russian Cardiology Research-and-Production Complex, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Antonova
1Department of Systemic Hypertension, Russian Cardiology Research-and-Production Complex, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Arkhipova
1Department of Systemic Hypertension, Russian Cardiology Research-and-Production Complex, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ekaterina Kobal
1Department of Systemic Hypertension, Russian Cardiology Research-and-Production Complex, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valery Masenko
1Department of Systemic Hypertension, Russian Cardiology Research-and-Production Complex, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergey Nakonechnikov
1Department of Systemic Hypertension, Russian Cardiology Research-and-Production Complex, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irina Chazova
1Department of Systemic Hypertension, Russian Cardiology Research-and-Production Complex, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: to assess the influence of endothelin receptor antagonist Bosentan on cellular Immunity parameters in pts with idiopathic pulmonary arterial hypertension (IPAH).

Methods: In the single-center comparative study we included 35 pts aged 35,2±9,6ys with IPAH confirmed by RHC (WHO Functional Class (FC) II-IV) without systemic inflammation signs. On top of stable therapy for at least 3 months Bosentan therapy was started 62,5 mg twice daily for 4 wks. At wk4 the patients were randomized 1:1 by the envelope method to have bosentan 125 or 250 mg/day. At baseline, at wk3 and wk12 visits the pts underwent the clinical and lab assessment (FC, 6-minute walking test (6-MWT), Echo, RHC,routine lab+CD-markers assessed by (fluorometry (Beckman Coulter FC 500).

Results: All cellular immunity parameters of IPAH pts remained within normal limits.

View this table:
  • View inline
  • View popup

Conclusion: 12wk therapy with Bosentan changed CD-markers levels. The daily dose of 125mg resulted in the increase of B-lymphocytes levels and slight decrease of activated T lymphocytes, In patients treated with Bosentan 250 mg we found decreased numbers of activated B - and T-lymphocytes.

  • Pulmonary hypertension
  • Immunology
  • Treatments
  • © 2012 ERS
Previous
Back to top
Vol 40 Issue Suppl 56 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension
Tamila Martynyuk, Kirill Zykov, Olga Antonova, Olga Arkhipova, Ekaterina Kobal, Valery Masenko, Sergey Nakonechnikov, Irina Chazova
European Respiratory Journal Sep 2012, 40 (Suppl 56) P407;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension
Tamila Martynyuk, Kirill Zykov, Olga Antonova, Olga Arkhipova, Ekaterina Kobal, Valery Masenko, Sergey Nakonechnikov, Irina Chazova
European Respiratory Journal Sep 2012, 40 (Suppl 56) P407;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Serum alkaline phosphatase may play a role in the differential diagnosis of sarcoidosis and tuberculosis?
  • Effects of comorbidities on the CAT score: A population-based study
  • Clinical approach to pulmonary sarcoidosis
Show more 1.13 Clinical Problems - Other

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society